Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Authors
Elander, NAughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Büchler, M
Greenhalf, W
Affiliation
Cancer Research U.K. Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UKIssue Date
2018-04
Metadata
Show full item recordAbstract
Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy.Citation
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. 2018, 118(7): 947-954 Br J CancerJournal
British Journal of CancerDOI
10.1038/s41416-018-0004-2PubMed ID
29515256Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/s41416-018-0004-2